Neuralox Product Research

Neuralox Advanced Memory Formula is formulated using leading research on Memory boosting neural nutrients. Each of Neuralox’s 3 systems is designed to support specific needs of your brain.

Neuralox's 3-Complex System - Triple Action

(1) Mind Protect System helps increase blood, nutrient, and oxygen delivery to the brain, while a powerful blend of antioxidants and anti inflammatory agents protects your mind from oxidative stress, free radical damage and premature cellular aging.

Alpha Lipoic acid – The Universal antioxidant since it is both fat- and water- soluble, unlike other antioxidants, It can cross the blood-brain barrier and hence, protects the brain and nerve tissue from oxidative damage. ALA is also consider one of the most effective compounds in fighting premature aging at the cellular level.

Bacopa monninera – A powerful antioxidant (Saponin) and anti-inflammatory herb that amplifies the effects of the body’s natural neural protective compounds and antioxidants.

Vinpocetine - Derived from periwinkle flower leaves, vinpocetine boosts memory function. In scientific tests and clinical trials, vinpocetine, was shown to improve blood circulation and nutrient delivery to the brain. Another amazing property of vinpocetine is that it not only aids memory enhancement, it actually repairs damage to the brain, protect the brain from breakdown. Increased blood and nutrient delivery to the brain not only improves memory function but also has shown benefit in hearing and eye sight.

(2) Brain Nourish System provides you with 6 essential vitamins and nutrients that your brain requires to protect, heal and function at optimum levels.

DHA - One of the major building blocks of the brain, the omega-3 fatty acid docosahexaenoic acid (DHA) is critical for optimal brain health and function at all ages of life. Researchers are now finding that DHA provides brain-boosting benefits in infants and aging adults.

Vitamin B6, B12, Folic acid - Complex B vitamins improve memory, any studies that have been conducted revealed that cognitive functions improve in time, if a treatment based on folate, vitamin B12 and B6 is followed. People who take these vitamins seem to process information at greater speeds. Complex B vitamins improve memory by reducing the stress and by protecting the nerves. It is a known fact that the deficit of vitamin B6 is usually correlated to nerve damage. When supplementing with vitamin B6, people can also reduce the depression, which is a main factor of memory loss. This vitamin regulates the GABA and serotonin neurotransmitters, which are tightly related to the levels of stress, depression and anxiety.

Phosphatidylserine – Phosphatidylserine is a phospholipid that is vital to your brain cells. Phospholipids are molecules containing both amino and fatty acids found in every cell membrane within our bodies. Actually, phosphatidylserine is universally present in living things from the most simple to the most complex. Phosphatidylserine has many known functions throughout all of our tissues and organs, but is most important as the key building block for the billions of cells that make up our brain.

Pantothenic acid (Vitamin B5) - Also a member of the B vitamin family, Vitamin B5 is a key precursor for the production of the neurotransmitter Acetyl Choline.

(3) AC Memory Maximizer System is developed to support your brain's healthy Acetyl Choline levels, the single most important factor for healthy memory and cognitive function.

Choline / Phosphocholine (Lecithin) - Choline and Phosphocholine are precursor for the production of neuro transmitters and are essential for cellular communication. The compound Choline is also required for the production of the neurotransmitter Acetyl Choline.

DMAE - Enhances brain activity as it readily moves through the brain-blood barrier then converting into Choline, it is believed that DMAE is effective in aiding brain function by stimulating the production of neurotransmitters such as Acetyl Choline. Dr Nicholas Perricone, renowned antiaging doctor, writes "Taking DMAE as a supplement has shown to increase cognitive function by improving memory and problem-solving ability. It has been shown to assist improvement in such disorders as attention deficit disorder (ADD)"

Acetyl L-carnitine – A power antioxidant that is key to energy production and neural protection. During the processing of ALC, the Acetyl group is released within the blood/brain to form a key component in the production for Acetyl Choline

Huperzine A – A natural derivative from Club moss, which is key to protecting your Acetyl Choline levels. Huperzine A is the only substance known to cross the blood-brain barrier and inhibit the action of the enzyme, acetylcholinesterase. Acetylcholinesterase acts by breaking down the neurotransmitter acetylcholine, by inhibiting this activity, Huperzine A directly leads to an increase in the concentration of the neurotransmitter acetylcholine.

The formula is developed to have a cumulative benefit on your overall brain health. Each system within Neuralox will begin delivering specific neural nutrients to your body and brain right away. Do not feel surprised if you begin feeling overall body benefits beyond just memory and mood, as Neuralox will elevate your levels of vitamins, anti oxidants and anti inflammatory nutrients.

An extra pill is okay - Neuralox designed for when your brain needs it most.

In times of high stress and memory demand it is safe to increase the dosage to 3 tablets daily. So when you have a stressful event such as a major deadline, an examination, you now have the support your need. Even during the holidays when you are strained and tired Neuralox can help, when you feel you have the blues and are mentally drained an extra tablet a day will give you added mental and mood support.

Clinical Research on the Key ingredients in Neuralox Advanced Memory Formula

Mind Protect System

Szakall S, Boros I, Balkay L, et al. Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: a PET study. J Neuroimaging. 1998 Oct;8(4):197-204.

Szilagyi G, Nagy Z, Balkay L, et al. Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study. J Neurol Sci. 2005 Mar 15;229-230:275-84.

Vas A, Gulyas B, Szabo Z, et al. Clinical and non-clinical investigations using positron emission tomography, near infrared spectroscopy and transcranial Doppler methods on the neuroprotective drug vinpocetine: a summary of evidences. J Neurol Sci. 2002 Nov 15;203-204:259-62.

Bonoczk P, Gulyas B, dam-Vizi V, et al. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull. 2000 Oct;53(3):245-54.

Molnar P, Erdo SL. Vinpocetine is as potent as phenytoin to block voltage-gated Na+ channels in rat cortical neurons. Eur J Pharmacol. 1995 Feb 6;273(3):303-6.

Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev. 2003;(1):CD003119.

Pereira C, Agostinho P, Oliveira CR. Vinpocetine attenuates the metabolic dysfunction induced by amyloid beta-peptides in PC12 cells. Free Radic Res. 2000 Nov;33(5):497-506.

Kiss B, Cai NS, Erdo SL. Vinpocetine preferentially antagonizes quisqualate/AMPA receptor responses: evidence from release and ligand binding studies. Eur J Pharmacol. 1991 Dec 10; 209(1-2):109-12.

Olah VA, Balla G, Balla J, Szabolcs A, Karmazsin L. An in vitro study of the hydroxyl scavenger effect of Cavinton . Acta Paediatr Hung . 1990;30:309-316.

Horvath B, Marton Z, Halmosi R, et al. In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine. Clin Neuropharmacol . 2002;25:37-42.

Santos M, Duarte A, Moreira P, Oliveira C. Synaptosomal response to oxidative stress: effect of vinpocetine. Free Radic Res . 2000;32:57-66.

Kagan V, Khan S, Swanson C, et al. Antioxidant action of thioctic acid and dihydrolipoic acid. Free Radic Biol Med 1990;9S:15.

Kagan VE, Shvedova A, Serbinova E, et al. Dihydrolipoic acid-a universal antioxidant both in the membrane and in the aqueous phase. Reduction of peroxyl, ascorbyl, and chromanoxyl radicals. Biochem Pharmacol. 1992; 44:1637-1649.

Biewenga GP Haenen GRMM Bast A (1997). "The pharmacology of the antioxidant lipoic acid". Gen Pharmacol 29: 315–331.

Packer L, Witt EH, and Tritschler HJ (1995). "alpha-Lipoic acid as a biological antioxidant". Free Radic Biol Med 19: 227–250.

Biewenga GP Haenen GRMM Bast A (1997). "The pharmacology of the antioxidant lipoic acid". Gen Pharmacol 29: 315–331.

G. Aliev, J. Liu, J. C. Shenk, K. Fischbach, G. J. Pacheco, S. G. Chen, M. E. Obrenovich, W. F. Ward, A. G. Richardson, M. A. Smith, E. Gasimov, G. Perry, B. N. Ames (2008). "Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats". J. Cell. Mol. Med. Epub ahead of print: 080329002216155.

Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem. 2004;11(9):1135-1146.

Jones W, Li X, Qu ZC, Perriott L, Whitesell RR, May JM. Uptake, recycling, and antioxidant actions of alpha-lipoic acid in endothelial cells. Free Radic Biol Med. 2002;33(1):83-93.

Suh JH, Moreau R, Heath SH, Hagen TM. Dietary supplementation with (R)-alpha-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Rep. 2005;10(1):52-60.

Yamamoto H, Watanabe T, Mizuno H, et al. The antioxidant effect of DL-alpha-lipoic acid on copper-induced acute hepatitis in Long-Evans Cinnamon (LEC) rats. Free Radic Res. 2001;34(1):69-80.

Hager K, Marahrens A, Kenklies M, Riederer P, Munch G. Alpha-lipoic acid as a new treatment option for Alzheimer type dementia. Arch Gerontol Geriatr. 2001;32(3):275-282

A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Neurology. 1998; 50(3):645-651.

K Anbarsi et al. Effect of bacoside A on brain antioxidant status in cigarette smoke exposed rats . Life Science, 2006 , 78(12).

Roodenrys, Steven Ph.D., et al. (2002). "Chronic Effects of Brahmi (Bacopa monnieri) on Human Memory". Neuropsychopharmacology 27: 279–281.

Nathan, PJ, et al. (2004). "Effects of a combined extract of Ginkgo biloba and Bacopa monniera on cognitive function in healthy humans". Hum. Psychopharmacol. 19: 91–96.

Ghosal. S, Bhattacharya SK (1980). "Anxiolytic activity of a standardized extract of Bacopa monniera in an experimental study". Phytomedicine 5: 133–148.

Negi KS, Singh YD, Kushwaha KP, Rastogi CK, Rathi AK, Srivastava JS, Asthana OP, Gupta RC, Lucknow G. "Clinical evaluation of memory enhancing properties of Memory Plus in children with Attention Deficit Hyperactivity Disorder." Indian Journal of Psychiatry, 2000 Apr; 42(2) Supplement

Russo A, Izzo AA, Borrelli F, Renis M, Vanella A. Free radical scavenging capacity and protective effect of Bacopa monniera L. on DNA damage. Phytother Res. 2003 Sep; 17(8): 870-5.

Brain Nourish System

Riggs KM, Spiro A, 3rd, Tucker K, Rush D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr. 1996; 63(3):306-314.

Deijen JB, van der Beek EJ, Orlebeke JF, van den Berg H. Vitamin B-6 supplementation in elderly men: effects on mood, memory, performance and mental effort. Psychopharmacology (Berl). 1992; 109(4):489-496.

Bryan J, Calvaresi E, Hughes D. Short-term folate, vitamin B-12 or vitamin B-6 supplementation slightly affects memory performance but not mood in women of various ages. J Nutr. 2002;132(6):1345-1356.

Balk EM, Raman G, Tatsioni A, Chung M, Lau J, Rosenberg IH. Vitamin B6, B12, and folic acid supplementation and cognitive function: a systematic review of randomized trials. Arch Intern Med. 2007;167(1):21-30.

Talbott MC, Miller LT, Kerkvliet NI. Pyridoxine supplementation: effect on lymphocyte responses in elderly persons. Am J Clin Nutr. 1987; 46(4):659-664.

Ishrat T, Hoda MN, Khan MB, Yousuf S, Ahmad M, Khan MM, Ahmad A, Islam F. Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer’s type (SDAT). Eur Neuropsychopharmacol. 2009 Mar 27. Published Online Ahead of Print

Srimal RC, Khanna NM, Dhawan BN. A preliminary report on anti inflammatory activity of curcumin. Int J Pharm 1971;3:10.

Mukhopadhyay A, Basu N, Ghatak N. Anti-inflammatory and irritant activities of curcumin analogues in rats. Agents Actions 1982;12:508-15.

Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (Diferuloyl methane). Indian J Med Res 1980;71:632-43.

Satoskar RR, Shah SJ, Shenoy SG. Evaluation of anti-inflammatory property of curcumin in patients with post operative inflammation. Int J Clin Pharmacol Ther Toxicol 1986;24:651-4.

Ebly EM, Schaefer JP, Campbell NR, Hogan DB. Folate status, vascular disease and cognition in elderly Canadians. Age Ageing. 1998; 27(4):485-491.

Luchsinger JA, Tang MX, Miller J, Green R, Mayeux R. Relation of higher folate intake to lower risk of Alzheimer disease in the elderly. Arch Neurol. 2007;64(1):86-92.

Morris MC, Evans DA, Schneider JA, Tangney CC, Bienias JL, Aggarwal NT. Dietary folate and vitamins B-12 and B-6 not associated with incident Alzheimer's disease. J Alzheimers Dis. 2006;9(4):435-443.

Morris MC, Evans DA, Bienias JL, et al. Dietary folate and vitamin B12 intake and cognitive decline among community-dwelling older persons. Arch Neurol. 2005;62(4):641-645.

Solini A, Santini E, Ferrannini E. Effect of short-term folic acid supplementation on insulin sensitivity and inflammatory markers in overweight subjects. Int J Obes (Lond). 2006 Aug;30(8):1197-202.

Wang HX, Wahlin A, Basun H, Fastbom J, Winblad B, Fratiglioni L. Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology. 2001; 56(9):1188-1194.

Nourhashemi F, Gillette-Guyonnet S, Andrieu S, et al. Alzheimer disease: protective factors. Am J Clin Nutr. 2000; 71(2):643S-649S.

Eussen SJ, de Groot LC, Joosten LW, et al. Effect of oral vitamin B-12 with or without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: a randomized, placebo-controlled trial. Am J Clin Nutr. 2006; 84(2):361-370.

Penninx BW, Guralnik JM, Ferrucci L, Fried LP, Allen RH, Stabler SP. Vitamin B(12) deficiency and depression in physically disabled older women: epidemiologic evidence from the Women's Health and Aging Study. Am J Psychiatry. 2000; 157(5):715-721.

Tahiliani, A.G. & Beinlich, C.J. (1991) Pantothenic acid in health and disease. Vitamins and Hormones 46: 165-228.

Slyshenkov, VS, Dymkowska, D, Wojtczak, L. (2004). Pantothenic acid and patothenol increase biosynthesis of glutathione by boosting cell energetics. FEBS Lett. 569(1-3):169-72.

Gaddi A, Descovich GC, Noseda G, et al. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia. Atherosclerosis. 1984;50(1):73-83.

Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG. (2005 Oct). "A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease". J Clin Invest. 115(10): 2774–83.

McNamara RK, Hahn CG, Jandacek R, et al. (2007). "Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder". Biol. Psychiatry 62 (1): 17–24.

Kyle DJ, Schaefer E, Patton G, Beiser A. Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia. Lipids. 1999;34 Suppl:S245.

Tully AM, Roche HM, Doyle R, et al. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr. 2003; 89(4):483-489.

Wurtman, R.J. Synapse formation and cognitive brain development: effect of docosahexaenoic acid and other dietary constituents. Metabolism. 2008, 57 Suppl 2:S6-10.

Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG. pmid=16151530 (2005 Oct). "A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease". J Clin Invest. 115(10): 2774–83.

Gamoh S, Hashimoto M, Hossain S, Masumura S. Chronic administration of docosahexaenoic acid improves the performance of radial arm maze task in aged rats.Clin Exp Pharmacol Physiol. 2001 Apr;28(4):266-70.

Hirayama S, Masuda Y, Rabeler R (September/October 2006). "Effect of phosphatidylserine administration on symptoms of attention-deficit/hyperactivity disorder in children". Agro Food 17 (5): 32–36.

Crook, T. H.; R. M. Klatz (ed) (1998). Treatment of Age-Related Cognitive Decline: Effects of Phosphatidylserine in Anti-Aging Medical Therapeutics. 2. Chicago: Health Quest Publications. pp. 20–29.

Amaducci L. Phosphatidylserine in the treatment of Alzheimer’s disease: Results of a multicenter study. Psychopharmacol Bull. 1988;24:130-134.

Delwaide PJ, Gyselynck-Mambourg AM, Hurlet A, et al. Double-blind randomized controlled study of phosphatidylserine in senile demented patients. Acta Neurol Scand. 1986;73:136-140.

Engel RR, Satzger W, Gunther W, et al. Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. Eur Neuropsychopharmacol. 1992;2:149-155.

Funfgeld EW, Baggen M, Nedwidek P, et al. Double-blind study with phosphatidylserine (PS) in Parkinsonian patients with senile dementia of Alzheimer’s type (SDAT). Prog Clin Biol Res. 1989;317:1235-1246.

Maggioni M, Picotti GB, Bondiolotti GP, et al. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Acta Psychiatr Scand. 1990;81:265-270.

Dacaranhe CD, Terao J. A unique antioxidant activity of phosphatidylserine on iron-induced lipid peroxidation of phospholipid bilayers. Lipids. 36(10): 1105-1110.

AC Memory Maximizer

McCann JC, Hudes M, Ames BN. An overview of evidence for a causal relationship between dietary availability of choline during development and cognitive function in offspring. Neurosci Biobehav Rev. 2006; 30(5):696-712.

Whitehouse, P.J. The cholinergic deficit in Alzheimer's disease. Journal of Clinical Psychiatry. 1998; volume 59 (supplement 13): pages 19-22.

Buchman, A.L., Sohel, M., Brown, M., Jenden, D.J., Ahn, C., Roch, M. and Brawley, T.L. Verbal and visual memory improve after choline supplementation in long-term total parenteral nutrition: a pilot study. JPEN J Parenter Enteral Nutr. 2001, 25(1):30-5

Zangara, A. The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmacol Biochem Behav. 2003; 75(3):675–86.

Xu, S.S., Gao, Z.X., Weng, Z., Du, Z.M., Xu, W.A., Yang, J.S., Zhang, M.L., Tong, Z.H., Fang, Y.S., Chai, X.S., et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Zhongguo Yao Li Xue Bao. 1995; 16(5):391-5.

Zhang, H.Y., Zheng, C.Y., Yan, H., Wang, Z.F., Tang, L.L., Gao, X. and Tang, X.C. Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia. Chem Biol Interact. 2008; 175(1-3):396-402.

Wang, Z.F., Wang, J., Zhang, H.Y. and Tang, X.C. Huperzine A exhibits anti-inflammatory and neuroprotective effects in a rat model of transient focal cerebral ischemia. J Neurochem. 106(4):1594-603.

Mazurek, A. An open-label trial of huperzine A in the treatment of Alzheimer's disease. Alternat Ther. 2000;5(2):97-98.

W. Dimpfel, W. Wedekind, I. Keplinger, "Efficacy of dimethylaminoethanol (DMAE) containing vitamin-mineral drug combination on EEG patterns in the presence of different emotional states", European Journal Medical Research 8(5):183-191, 2003.

Fisman M, Mersky H, Helmes E. "Double-blind trial of 2-dimethylaminoethanol in Alzheimer's disease." American Journal of Psychiatry 138(7):970–972, 1981.

Higgins, J.P. & Flicker, L. Lecithin for dementia and cognitive impairment. Cochrane Database of Systematic Reviews. 2000. 2:CD001015.

Redox modulation of heat shock protein expression by acetylcarnitine in aging brain: relationship to antioxidant status and mitochondrial function. Calabrese V; Colombrita C; Sultana R; Scapagnini G; Calvani M; Butterfield D A; Stella A M Giuffrida (2006). Antioxidants & redox signaling 2006;8(3-4):404-16.

Lecithin treatment of cognitively impaired Parkinson's patients. Tweedy JR, Garcia CA. (1982) Eur J Clin Invest. 12(1):87-90.

Oral physostigmine and lecithin improve memory in Alzheimer disease. Thal LJ, Fuld PA, Masur DM, Sharpless NS. (1983). Ann Neurol. 13(5):491-6.

Improvement in quality of life in the elderly. Results of a placebo-controlled study on the efficacy and tolerability of lecithin fluid in patients with impaired cognitive functions. Volz HP, Hehnke U, Hauke W. (2004). MMW Fortschr Med. 146(Suppl 3-4):99-106. German.

Al-Majed AA, Sayed-Ahmed MM, Al-Omar FA, Al-Yahya AA, Aleisa AM, Al-Shabanah OA (August 2006). "Carnitine esters prevent oxidative stress damage and energy depletion following transient forebrain ischaemia in the rat hippocampus". Clin. Exp. Pharmacol. Physiol. 33 (8): 725–33.

Wilson AD, Hart A, Brännström T, Wiberg M, Terenghi G (2007). "Delayed acetyl-L-carnitine administration and its effect on sensory neuronal rescue after peripheral nerve injury". J Plast Reconstr Aesthet Surg 60 (2): 114–8.

Beal MF (2003). "Bioenergetic approaches for neuroprotection in Parkinson's disease". Ann. Neurol. 53 Suppl 3: S39–47; discussion S47–8.

Arrigo A, Casale R, Buonocore M et al: Effects of acetyl-L-carnitine on reaction times in patients with cerebrovascular insufficiency. Int J Clin Pharmacol Res 1990; 10(1-2):133-137.

Arrigo A, Clano E, Casale R et al: The effects of L-acetylcarnitine on reaction times in patients with cerebrovascular insufficiency: a double-blind cross-over study. Clin Trials J 1988; 25(suppl 1):47-56.

Bonavita E, Bertuzzi D, Bonavita J et al: L-Acetylcarnitine (L-Ac) (Branigen) in the long-term symptomatic treatment of senile dementia. Clin Trials J 1988; 25(4):227-237.

Montgomery SA, Thal LJ, & Amrein R: Meta-analysis of double blind randomized controlled clinical trials of acteyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol 2003; 18:61-71.